AstraZeneca has unveiled findings of a new analysis of data from the CVD-REAL study, showing a significant cut in the risk of all-cause death (ACD) in patients with type II diabetes taking SGLT-2 inhibitors.
13th March 2018
Biogen is buying Pfizer’s experimental drug PF-04958242, which is being developed for cognitive impairment associated with schizophrenia, in a deal that could be worth $590 million.
13th March 2018
US regulators have upheld a prior decision rejecting Hikma and Vectura’s generic formulation of GlaxoSmithKline's asthma and chronic obstructive pulmonary syndrome therapy Advair Diskus.
12th March 2018
Sanofi and Regeneron have pledged to make Praluent more accessible to patients as data show that the drug significantly cut the risk of cardiovascular events in high-risk patients.
12th March 2018
AstraZeneca and research arm MedImmune have announced a longer wait for survival data from a closely-watched trial testing Imfinzi in advanced lung cancer.
12th March 2018
Cost regulators for NHS therapies in England and Wales say they are minded not to recommend funding for MSD’s Keytruda as a treatment for classical Hodgkin lymphoma, because its cost-effectiveness is uncertain.
12th March 2018
The European Commission has approved a label update to GlaxoSmithKline/Innoviva’s Relvar Ellipta, expanding the asthma therapy’s reach.
9th March 2018
Clinical researchers in the Americas have submitted essays for this year's competition and on 15 March, the authors and finalists will be identified at a meeting of the executive steering group.
9th March 2018
US regulatory advisors are backing use of Pfizer’s JAK inhibitor Xeljanz to treat adults with moderately to severely active ulcerative colitis (UC).
9th March 2018
Cytox has been awarded funding from Innovate UK for the clinical evaluation of its pioneering approach to Alzheimer’s disease risk assessment.
9th March 2018
The Royal College of Emergency Medicine is urging patients to lobby MPs for action to address the “serious challenges” facing Emergency Departments across the UK.
9th March 2018
Following a meeting of the executive steering group, PharmaTimes Media is delighted to reveal the 2018 International Clinical Researcher of the Year finalists...
8th March 2018
The All Wales Medicines Strategy Group has approved NHS funding for the use of UCB’s Vimpat in children with epilepsy.
8th March 2018
Roche/Chugai’s RoActemra has now won the backing of the National Institute of Health and Care Excellence for the treatment of eligible patients with giant cell arteritis (GCA).
8th March 2018
MSD has launched in the UK Europe’s first biosimilar to Roche/Genentech’s Herceptin, providing an alternative option for treating early breast cancer, metastatic breast cancer and metastatic gastric cancer.
8th March 2018
